<DOC>
	<DOCNO>NCT02117622</DOCNO>
	<brief_summary>This study conduct Asia . The aim study evaluate long term safety efficacy Tresiba® ( insulin degludec ) patient diabetes mellitus routine clinical practice India .</brief_summary>
	<brief_title>A Non-interventional , Post Marketing Surveillance ( PMS ) Study Tresiba® ( Insulin Degludec ) Evaluate Long Term Safety Efficacy Patients With Diabetes Mellitus Routine Clinical Practice India</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 1</mesh_term>
	<mesh_term>Insulin , Globin Zinc</mesh_term>
	<mesh_term>Insulin</mesh_term>
	<mesh_term>Insulin , Long-Acting</mesh_term>
	<criteria>Informed consent obtain studyrelated activity ( Study relate activity procedure relate recording data accord protocol ) . The historical data include data inform consent obtain ( e.g . glycosylated haemoglobin ( HbA1c ) , fast plasma glucose ( FPG ) , severe hypoglycaemia start Tresiba® therapy ) use baseline data Patients insulin require diabetes mellitus schedule start treatment Tresiba® base clinical judgment treat physician Known suspect allergy Tresiba® , active substance excipients Previous participation study Mental incapacity , unwillingness language barrier preclude adequate understanding cooperation Patients previously Tresiba® therapy Patients participate study clinical trial Patients pregnant , breast feeding intention become pregnant within follow 12 month</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>